Why Pharma Giants Are Outsourcing Drug Manufacturing to CDMOs
All You Need to Know About Outsourcing Drug Manufacturing & Development to CDMO
5 Reasons Why More Pharma Companies Are Strengthening CDMO Relationships
Quality Risk Management in Pharmaceutical Industry
Neuland Announces New Vision and Values Statements
The Essential Role of Intellectual Property Expertise in a Pharmaceutical API Company
Achieving Drug Development Success: Inside Neuland’s Three-Pillar Project Management Strategy
From the Neuland Reading Room: Peptide Trends in 2024
Zero Liquid Discharge: A Pharma Industry Commitment to Environmental Sustainability
The Pharma Supply Chain: Reshaping Itself for The New Normal
Redefining Excellence: Neuland Unveils a Refreshed Brand Identity
From the Neuland Reading Room: A Check-in on 2024 Trends in the CDMO Industry
How to Ensure Effective Technology Transfer to CDMOs
Why Agility Matters When Choosing an API Contract Manufacturing Partner
API Particle Size Part 2: New & Emerging Technologies Impacting Particle Size
API Particle Size Part I: Overcoming the Challenges to Ensure Quality Pharmaceutical Products
Scaling-up Active Pharmaceutical Ingredient (API) Chemistry for Phase 3 Clinical Trials and Bulk Manufacturing for a Potentially Novel Treatment for Schizophrenia
R&D Expert Talks Pharma API Scale Optimization
The Crucial Role of Crystallization in Drug Substances Development
What Pharmacological Advantages Can Deuterated APIs Deliver?
Integrating Sustainability into Pharma Manufacturing
8 Ways Effective Supply Chain Management Can Minimize Pharmaceutical Supply Chain Challenges
Advancing a Cholesterol Lowering Drug at the Height of the Pandemic
ESG in Pharma: Building Sustainable Businesses
How Neuland’s Process Engineering Lab Supports Robust Design and Minimizes Risk
Putting Customers First: Customer Centricity in Pharma API Manufacturing
3 Key Elements of a Successful Hydrogenation Scale-Up
Why is Pharmaceutical Green Chemistry Use on the Rise?
Regulatory Starting Materials: How to Source, Analyze and Validate Suppliers (Part I)
Exploring Neuland’s Therapeutic Segments: Focus on CNS
Green Chemistry by Design (GCbD): The Earlier, The Better for Pharmaceutical APIs
Deuterated Drug Molecules: Perfecting the Gamechanger
What Does it Take to Become a Specialist in Late-Phase CMS?
API Production: Building a Process Safety Culture
Looking for an API Supplier? 5 Things to Consider (Updated)
Nitrosamine Impurities and How Companies are Addressing the Crisis
Successful Pharmaceutical Project Management
Complex Synthesis in Action: Achieving a Commercial-Scale 16 AA Peptide
A Guide to Sourcing Pharmaceutical Peptide APIs
Case Studies from Neuland’s Process Engineering Lab
Overcoming Challenges in Complex Peptide Purification
Welcome, Unit 3!
QbD and Evaluating ‘What-If’ Drug Manufacturing Scenarios
NCEs Versus Generics – Adjusting Project Tactics & Objectives to Maximize Success
Synthetic Route Scouting: Factors to Improve API Manufacturing
How to Select a Peptide Synthesis Technique
Leveraging QbD for API Scale Up
5 Common Challenges Scaling Up an API
How Process Engineering Techniques Result in Cost-Effective Products
API Manufacture of Deuterated Molecules
Advantages of a Pure-Play API Contract Manufacturer
APIs & Continuous Flow Manufacturing
Challenges with API Micronization Techniques for Use in Injectables and Medical Devices
Advances in the Synthesis of Peptide Therapeutics: Clear Advantages…and Some Barriers
Genotoxic Impurities – Increasing Vigilance, But Still Some Uncertainty
6 Properties of API Synthesis that Affect Yield, Delivery Date & Purity
Contract Drug Manufacturing R&D: from Route Scouting to Kilo Labs
The Benefits of Synthesis Scouting
Analytical Capabilities and Drug Quality – Key to Successful Pharma Outsourcing
The New Look of Neuland
Peptide Synthesis: Solution Phase, Solid Phase or Hybrid?
Neuland Labs Receives 2013 CMO Leadership Award for Regulatory Excellence
